Evogene Stock Price, News & Analysis

Lavie Bio, a subsidiary of Evogene (Nasdaq: EVGN), has appointed Amit Noam as Chief Executive Officer, effective April 16, 2023. Noam possesses significant experience in the agriculture and healthcare sectors, having previously served as COO of AgriTask and held roles at Teva Pharmaceuticals. He aims to enhance Lavie Bio's mission in improving food quality and sustainability through microbiome-based products powered by Evogene's AI tech. Ofer Haviv, Chairperson of Lavie Bio, expressed confidence in Noam's leadership for advancing manufacturing and sales of their bio-stimulant, Thrivus™, and for progressing their pipeline, including the anticipated LAV311 bio-fungicide launch in 2024.

Biomica Ltd., a clinical-stage biopharmaceutical company and subsidiary of Evogene (NASDAQ: EVGN), announced that Dr. Shiri Meshner, VP of R&D, will present at the Pharmabiotics 2023 Conference in Lyon, France, on March 21-22, 2023. Dr. Meshner's presentation, titled Biomica's BMC128 - a Rationally Designed LBP Consortium's Journey to the Clinic, will occur on March 21 at 3:40 PM CET. Biomica's proprietary BMC128, consisting of four live bacterial strains, showed significant tumor volume reduction and improved survival compared to anti-PD-1 therapy in preclinical studies. Currently, BMC128 is undergoing a Phase 1 trial (NCT05354102) in patients with non-small cell lung cancer, melanoma, and renal cell carcinoma.

Evogene Ltd. (NASDAQ: EVGN) announced its 2022 financial results, showing significant advancements in AI-driven product development through subsidiaries like Lavie Bio and Biomica. Fourth-quarter revenues surged to $660K from $311K year-on-year, contributing to a total annual revenue of $1.7M, up from $0.9M in 2021. The company's cash position remains strong at approximately $35M. However, operating losses decreased to $3.8M for Q4, down from $8.7M last year, with a full-year net loss of $29.8M, slightly improved from $30.4M in 2021. The company continues to foster strategic partnerships and aims for growth despite competitive market challenges.

Lavie Bio, a subsidiary of Evogene (Nasdaq: EVGN), announced its participation at the World Agri-Tech Conference in San Francisco on March 14-15, 2023. The company will host a roundtable discussion entitled 'Farm to Fork or Fork to Farm' on March 15, focusing on the sustainability value chain. Lavie Bio is also a sponsor of the conference, which attracts over 2,000 participants from the global ag-tech ecosystem. The company aims to enhance food quality and agricultural productivity through microbiome-based products, leveraging its MicroBoost AI tech-engine.

Ag Plenus Ltd., a subsidiary of Evogene (NASDAQ: EVGN), will participate in the World Agri-Tech Conference in San Francisco on March 14-15, 2023. Represented by Merav Beiman and Mirit Ram, the conference aims to unite over 2,000 industry leaders, growers, and investors to discuss innovations in agriculture technology. Ag Plenus focuses on sustainable crop protection solutions, utilizing predictive biology and artificial intelligence through its ChemPass AI tech-engine. The company collaborates with industry leaders, including Corteva, to tackle pesticide resistance.

Biomica, a clinical-stage biopharmaceutical company and subsidiary of Evogene Ltd. (NASDAQ: EVGN), announced its participation in the 2023 ECCO Annual Meeting in Copenhagen, Denmark, from March 1 to 4, 2023. The conference focuses on advancements in Inflammatory Bowel Diseases (IBD). Professor Yehuda Ringel, Biomica's CSO, will present a poster titled "Anti-inflammatory Effect and Mechanism of Action of BMC333" during the conference on March 3, 2023. The poster will be accessible until June 4, 2023, and Professor Ringel is available for one-on-one meetings throughout the event.

Evogene Ltd. (NASDAQ: EVGN) will participate in the 35th Annual ROTH Conference in Dana Point, California, on March 13-14, 2023. The event will include one-on-one meetings, industry panels, and presentations, attracting institutional investors and analysts. Executive VP Eyal Ronen will be available for discussions with investors on March 13. Interested investors can arrange meetings through Roth representatives or Evogene's investor relations team, which offers both in-person and virtual options. Evogene focuses on computational biology to enhance the development of life-science products through innovative technologies like MicroBoost AI, ChemPass AI, and GeneRator AI.

Lavie Bio Ltd., a subsidiary of Evogene (NASDAQ: EVGN), announced successful results from field trials of its bio-fungicides, LAV311 and LAV321, conducted in 2022. These products aim to combat fungal diseases like bunch rot and blight while reducing chemical reliance in agriculture. The bio-fungicides showed improved efficacy over existing commercial benchmarks, paving the way for potential commercialization in 2024, pending EPA registration. Lavie Bio's advancements cater to the growing demand for eco-friendly solutions in agriculture amidst an estimated $21 billion global fungicide market, projected to grow at a CAGR of 6.4%.

Evogene Ltd. (NASDAQ: EVGN) announced it will release its financial results for the fourth quarter and full year 2022 on March 9, 2023. A conference call is scheduled for 9am ET that same day, where management will discuss the results. The company focuses on utilizing advanced computational biology technologies to enhance life-science product development. Evogene operates through subsidiaries, developing products in areas like human microbiome therapeutics and ag-chemicals.

For investors, the call can be accessed via telephone or live webcast on the company's website.